CompletedPhase 2NCT05227820

Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Neurological Associates of West Los Angeles
Principal Investigator
Sheldon Jordan
Neurological Associates The Interventional Group/The Regenesis Project
Intervention
NE3107(drug)
Enrollment
23 enrolled
Eligibility
55-89 years · All sexes
Timeline
2022 – 2022

Study locations (1)

Collaborators

BioVie Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05227820 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials